v3.25.2
Summary of Significant Accounting Policies - Summary of Segment Reconciliation (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total research and development $ 11,580 $ 9,493 $ 22,057 $ 17,501
Total selling, general and administrative 3,318 3,215 7,332 6,345
Salaries and staff costs        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total research and development 2,134 1,714 4,103 3,582
Total selling, general and administrative 849 807 1,775 1,714
Stock-based compensation        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total research and development 672 397 1,187 786
Total selling, general and administrative 1,011 782 1,861 1,517
Clinical trials, outside services, and lab supplies        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total research and development 8,306 6,950 15,803 12,202
Outside services and professional fees        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total selling, general and administrative 1,062 1,167 2,860 2,150
Facilities and other        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total research and development 468 432 964 931
Total selling, general and administrative $ 396 $ 459 $ 836 $ 964